CBX

  Jing Medicine (和径医药) has submitted the IND application for HJ-002-03, an EGFR-PROTAC, intended for patients with non-small cell lung cancer in China. HJ-002 is the first PROTAC in the IND stage developed by Jing Medicine. https://doi.org/10.1016/j.ejmech.2022.114533 In 2022, Jing Medicine received IND approval for HJM-353 , an EED inhibitor, in both China and the United States, however, no clinical study has been initiated as of yet. In 2021, Jing Medicine filed a patent (WO2022268229) claiming the PROTACs targeting EGFR, ALK, and ROS1.  These CRBN-based PROTACs, designed with Brigatinib analogs that target ALK and EGFR kinases, may offer a potential new approach for treating lung cancer by inducing targeted protein degradation.  Brigatinib and Embodiments in the Patent E95 and E123 demonstrated potent degradation activity, with DC50 values around single-digit nM and achieving over 90% degradation (Dmax) for EGFR-DTC (Del19/T790M/C797S), EGFR-LTC (EGFR L858R/T790M/C797S), and EGFR-